GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioverativ Inc (NAS:BIVV) » Definitions » ROIC %

Bioverativ (Bioverativ) ROIC % : 56.77% (As of Dec. 2017)


View and export this data going back to 2017. Start your Free Trial

What is Bioverativ ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Bioverativ's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2017 was 56.77%.

As of today (2024-04-25), Bioverativ's WACC % is 0.00%. Bioverativ's ROIC % is 0.00% (calculated using TTM income statement data). Bioverativ earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Bioverativ ROIC % Historical Data

The historical data trend for Bioverativ's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioverativ ROIC % Chart

Bioverativ Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17
ROIC %
- -114.08 29.30 83.19 44.12

Bioverativ Quarterly Data
Dec13 Dec14 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 163.95 58.15 42.68 25.46 56.77

Competitive Comparison of Bioverativ's ROIC %

For the Biotechnology subindustry, Bioverativ's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioverativ's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioverativ's ROIC % distribution charts can be found below:

* The bar in red indicates where Bioverativ's ROIC % falls into.



Bioverativ ROIC % Calculation

Bioverativ's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2017 is calculated as:

ROIC % (A: Dec. 2017 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2016 ) + Invested Capital (A: Dec. 2017 ))/ count )
=447.2 * ( 1 - 21.31% )/( (638.7 + 956.4)/ 2 )
=351.90168/797.55
=44.12 %

where

Bioverativ's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2017 is calculated as:

ROIC % (Q: Dec. 2017 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2017 ) + Invested Capital (Q: Dec. 2017 ))/ count )
=471.6 * ( 1 - -18.94% )/( (1019.8 + 956.4)/ 2 )
=560.92104/988.1
=56.77 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2017) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioverativ  (NAS:BIVV) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Bioverativ's WACC % is 0.00%. Bioverativ's ROIC % is 0.00% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Bioverativ ROIC % Related Terms

Thank you for viewing the detailed overview of Bioverativ's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioverativ (Bioverativ) Business Description

Traded in Other Exchanges
N/A
Address
Bioverativ Inc is a biotech focused on rare blood disorders and has two marketed hemophilia products: Eloctate (hemophilia A) and Alprolix (hemophilia B). Bioverativ spun off from Biogen in February 2017. Bioverativ's partner Swedish Orphan Biovitrum holds rights to these therapies and pipeline hemophilia therapies in many markets outside the U.S. Bioverativ is building a pipeline in rare blood-related disorders, such as TNT009 (part of the True North acquisition) in cold agglutinin disease and other hematology-focused drug candidates. Sanofi's pending acquisition of Bioverativ was announced in January 2018.
Executives
Alexander J Denner director C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Brian S Posner director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
John Cox director, officer: Chief Executive Officer C/O BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
John Greene officer: EVP, CFO and Treasurer 51 LIME STREET, LONDON X0 EC3M 7DQ
Geno J Germano director 5 GIRALDA FARMS, MADISON NJ 07940
Louis J Paglia director C/O UIL HOLDINGS CORP, 157 CHURCH STREET, NEW HAVEN CT 06506
Anna Protopapas director MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Diantha Duvall officer: Chief Accounting Officer C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Vivaldi Coelho Rogerio officer: EVP, Chief Global Therapeutics 225 SECOND AVENUE, WALTHAM MA 02451
Harris Timothy J.r. officer: EVP, R & D C/O BG MEDICINE, 610 LINCOLN STREET NORTH, WALTHAM MA 02451
Lucia Celona officer: EVP, HR & Corp Commun. Officer BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Richard Brudnick officer: EVP, Business Development BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Biogen Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142

Bioverativ (Bioverativ) Headlines

From GuruFocus

5 Companies Hit 52-Week Highs

By yifan900 yifan900 05-29-2018

Seeking Value in Biotech: Bioverativ

By Mark Yu Mark Yu 06-29-2017

Jeff Ubben Buys 1, Sells 1 in 1st Quarter

By Sydnee Gatewood Sydnee Gatewood 05-24-2017